Matteo Lambertini, MD PhD· @matteolambe · X·· 21 小时前评分70
正文 · 机器翻译
#ESMO26 大会 #BreastCancer 分会口头报告摘要：在内分泌耐药患者中，使用 #CDK4 抑制剂 #atirmociclib 联合 #fulvestrant 的2期结果，由杰出的 @antgiorda 🇮🇹 报告
@OncoAlert @myESMO @Annals_Oncology
228 浏览 · 10 赞 · 6 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.org来源：Matteo Lambertini, MD PhD · x.com